


We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious and rare diseases:

Oncology



Infectious Diseases

Drug Class	Product Candidate	Indication (Targets)	Pre-clinical	Phase 1	Phase 2	Phase 3	Commercial	Rights/Collaborator
mRNA	BNT162b2	COVID-19						Fosun Pharma (China), Pfizer (Global, except China)
	BNT161	Seasonal influenza				 		Pfizer
	Un-named program	Malaria				 - 		Fully-owned
	Un-named program	HIV				i I !		Bill & Melinda Gates Foundation
	Un-named program	Tuberculosis						Bill & Melinda Gates Foundation
	5 un-named programs	Undisclosed indications				 		Fully-owned
Antibodies	Undisclosed program	COVID-19				 		Fully-owned

- 1 BNT113 and BNT115 are currently being studied in investigator-initiated Phase 1 trials
- 2 Checkpoint Inhibitor
- 3 Small Molecule Immunomodulators